Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation-Reference-Cited by-同舟云学术

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Published:2022-10-03 Issue:2 Volume:89 Page:751-761
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

van den Dries Carline J.¹,Pajouheshnia Romin²^ORCID,van den Ham Hendrika A.²,Souverein Patrick²^ORCID,Moons Karel G. M.¹,Hoes Arno W.¹,Geersing Geert‐Jan¹,van Doorn Sander¹

Affiliation:

1. Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

2. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15534

Reference38 articles.

1. The Changing Landscape for Stroke Prevention in AF

2. Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?

3. Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

4. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study;International Journal of Cardiology;2024-08